Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Compare

11,936 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMY Analyst Ratings

Moderate Buy

8 Buy

11 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMY Stock 12 Month Forecast

Average Price Target

$56.13

▲(0.65% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $56.13 with a high forecast of $68.00 and a low forecast of $37.00. The average price target represents a 0.65% change from the last price of $55.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","69":"$69","44.25":"$44.3","52.5":"$52.5","60.75":"$60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.133333333333326,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,44.25,52.5,60.75,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.31,54.440000000000005,55.57,56.7,57.83,58.96,60.09,61.22,62.35,63.480000000000004,64.61,65.74000000000001,66.87,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.31,53.52717948717949,53.744358974358974,53.96153846153846,54.178717948717946,54.39589743589743,54.61307692307692,54.83025641025641,55.047435897435896,55.26461538461538,55.48179487179487,55.698974358974354,55.91615384615384,{"y":56.133333333333326,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.31,52.05538461538462,50.800769230769234,49.54615384615385,48.291538461538465,47.03692307692308,45.7823076923077,44.527692307692305,43.27307692307693,42.01846153846154,40.76384615384616,39.50923076923077,38.254615384615384,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.25,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.53,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$56.13

Lowest Price Target$37.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Risinger

Leerink Partners

$54→$60

Buy

7.58%

Upside

Reiterated

01/13/26

Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY)

Courtney Breen

Bernstein

Hold

―

Reiterated

01/13/26

Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

01/12/26

Evan Seigerman

BMO Capital

$47

Hold

-15.73%

Downside

Reiterated

01/09/26

Louise Chen

Scotiabank

$53→$60

Hold

7.58%

Upside

Reiterated

01/09/26

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Trung Huynh

UBS

$46→$65

Buy

16.55%

Upside

Upgraded

01/07/26

Bristol Myers upgraded to Buy from Neutral at UBSBristol Myers upgraded to Buy from Neutral at UBS

Jasper Hellweg

Argus Research

Hold

―

Reiterated

01/07/26

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT), InMode (NASDAQ: INMD) and Bristol-Myers Squibb (NYSE: BMY)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$55→$57

Hold

2.21%

Upside

Reiterated

01/06/26

Berenberg Bank Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

$62

Buy

11.17%

Upside

Reiterated

01/06/26

Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)

Jason Gerberry

Bank of America Securities

$61

Buy

9.38%

Upside

Reiterated

01/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Geoff Meacham

Citi

$45→$53

Hold

-4.97%

Downside

Reiterated

01/05/26

Bristol Myers price target raised to $53 from $45 at CitiBristol Myers price target raised to $53 from $45 at Citi

Seamus Fernandez

Guggenheim

$62

Buy

11.17%

Upside

Reiterated

12/22/25

Bristol-Myers Squibb (BMY) Receives a Buy from Guggenheim

Asad Haider

Goldman Sachs

$51→$57

Hold

2.21%

Upside

Reiterated

12/15/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Terence Flynn

Morgan Stanley

$36→$37

Sell

-33.66%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Risinger

Leerink Partners

$54→$60

Buy

7.58%

Upside

Reiterated

01/13/26

Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY)

Courtney Breen

Bernstein

Hold

―

Reiterated

01/13/26

Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)

Srikripa Devarakonda

Truist Financial

Buy

―

Reiterated

01/12/26

Evan Seigerman

BMO Capital

$47

Hold

-15.73%

Downside

Reiterated

01/09/26

Louise Chen

Scotiabank

$53→$60

Hold

7.58%

Upside

Reiterated

01/09/26

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Trung Huynh

UBS

$46→$65

Buy

16.55%

Upside

Upgraded

01/07/26

Bristol Myers upgraded to Buy from Neutral at UBSBristol Myers upgraded to Buy from Neutral at UBS

Jasper Hellweg

Argus Research

Hold

―

Reiterated

01/07/26

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (NASDAQ: PHAT), InMode (NASDAQ: INMD) and Bristol-Myers Squibb (NYSE: BMY)

Unknown Analyst

Berenberg Bank

Not Ranked

Berenberg Bank

$55→$57

Hold

2.21%

Upside

Reiterated

01/06/26

Berenberg Bank Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

David Amsellem

Piper Sandler

$62

Buy

11.17%

Upside

Reiterated

01/06/26

Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)

Jason Gerberry

Bank of America Securities

$61

Buy

9.38%

Upside

Reiterated

01/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Geoff Meacham

Citi

$45→$53

Hold

-4.97%

Downside

Reiterated

01/05/26

Bristol Myers price target raised to $53 from $45 at CitiBristol Myers price target raised to $53 from $45 at Citi

Seamus Fernandez

Guggenheim

$62

Buy

11.17%

Upside

Reiterated

12/22/25

Bristol-Myers Squibb (BMY) Receives a Buy from Guggenheim

Asad Haider

Goldman Sachs

$51→$57

Hold

2.21%

Upside

Reiterated

12/15/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Terence Flynn

Morgan Stanley

$36→$37

Sell

-33.66%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

3 Months

xxx

Success Rate

10/13 ratings generated profit

Average Return

+9.34%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +9.34% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

15/19 ratings generated profit

Average Return

+7.86%

reiterated a buy rating 2 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +7.86% per trade.

2 Years

xxx

Success Rate

12/13 ratings generated profit

Average Return

+19.42%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +19.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMY Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMY has received 20 Buy Ratings, 32 Hold Ratings, and 4 Sell Ratings. BMY average Analyst price target in the past 3 months is 56.13.

Each month's total comprises the sum of three months' worth of ratings.

BMY Financial Forecast

BMY Earnings Forecast

Next quarter’s earnings estimate for BMY is $1.55 with a range of $1.05 to $1.74. The previous quarter’s EPS was $1.63. BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Sales Forecast

Next quarter’s sales forecast for BMY is $12.24B with a range of $11.95B to $12.53B. The previous quarter’s sales results were $12.22B. BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BMY has Performed in-line its overall industry.

BMY Stock Forecast FAQ

What is BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 56.13.

What is BMY’s upside potential, based on the analysts’ average price target?

Bristol-Myers Squibb has 0.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMY a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Moderate Buy which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s price target?

The average price target for Bristol-Myers Squibb is 56.13. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $37.00. The average price target represents 0.65% Increase from the current price of $55.77.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of BMY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

BMY Analyst Ratings

BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

BMY Analyst Recommendation Trends

BMY Financial Forecast

BMY Earnings Forecast

BMY Sales Forecast

BMY Stock Forecast FAQ

Detailed List of Analyst Forecasts